We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
The FTC has asked Cephalon for information about settlements it made with four generic drug firms allowing them to market generic versions of Cephalon’s narcolepsy drug Provigil, according to documents filed with the SEC.
The FTC has cleared a pending merger between Teva and Ivax, but said the two companies must sell off manufacturing and/or marketing rights to 15 generic drugs, according to a Jan. 23 consent order.
Pharmaceutical firm Allergan, maker of the antiwrinkle treatment Botox, has signed a definitive merger agreement to buy breast implant maker Inamed for roughly $3.2 billion.
The boards of Alliance Medical and Vanguard Medical Concepts recently approved an agreement that would merge the two leading third-party reprocessors of single-use medical devices (SUDs).
The FTC has filed an amicus brief asking a federal appeals court to rehear a case against AstraZeneca and Barr Laboratories that charged that the drugmakers violated antitrust laws with their patent settlement over AstraZeneca's breast cancer drug Nolvadex.
In a surprise move last week, Boston Scientific offered $25 billion in cash and stock to purchase cardiac devicemaker Guidant, topping by $3.5 billion Johnson & Johnson’s (J&J) earlier bid to buy the firm.
Congress could craft legislation to close loopholes in the Hatch-Waxman Act that allow brand firms to launch authorized generics, regardless of the findings of an upcoming FTC study on the practice, according to an industry representative.
The FTC plans to investigate the competitive effects that authorized generics are having on the drug industry, yet another sign that the agency is taking a harder line against potentially anticompetitive deals between drugmakers.
The FTC is suing Barr Laboratories and Warner Chilcott, seeking to nullify a $20 million agreement to keep a generic version of Warner’s contraceptive Ovcon-35 off the market — a move that shows the FTC is taking a stronger stance against what it sees as anticompetitive deals within the drug industry, one analyst says.